Best Lawyers in America
O'Steen & Harrison, PLC is recognized by U.S. News and World Report as one of the best law firms in America. Our firm was designated as a Tier 1 law firm in Personal Injury Litigation in the organization's "Best Lawyers - Best Law Firms" rankings for 2022.
Top-Rated Law Firm
O'Steen & Harrison, PLC is rated AV Preeminent by the prestigious Martindale-Hubbell Law Directory. This is the highest possible designation and is reserved for law firms with the strongest legal ability and highest ethical standards.
Testosterone News
Low-T Drug Therapy Lawsuits Grow in Number
Jonathan V. O'Steen
August 6, 2014
More than 150 lawsuits already have been filed against manufacturers of low testosterone therapy drugs in the U.S. District Court for the Northern District of Illinois. This is the court in which low-T drug litigation has been consolidated into what is called "multidistrict litigation (MDL)" in the federal court system.
Attorney for Low-T Drug Patients Urges FDA to Prevent "Off Label" Use
Jonathan V. O'Steen
July 30, 2014
Phoenix attorney Jonathan O'Steen has asked the federal Food and Drug Administration (FDA) to take action to prevent off-label use of the testosterone therapy drugs AndroGel, AndroDerm, Axiron, Bio-T-Gel, Delatestryl, Depo-Testosterone, Fortesta, Striant, Testim and Testopel.
Androgel Manufacturer Wants Coordination of Low-T Lawsuits
Van O'Steen
February 12, 2013
In June, all testosterone therapy lawsuits previously filed in various federal courts throughout the United States were consolidated in a single court—the U.S. District Court for the Northern District of Illinois. The advantages of consolidation include efficiency, resource conservation, reduction of duplication in the trial preparation process and elimination of the possibility of conflicting rulings among different courts.
The Law Firm You Choose Makes a Difference
In the largest injury case in the history of the world, we were selected as the only Arizona law firm to represent the State of Arizona against American tobacco companies for the past, present and future costs of treating tobacco-related illnesses. As a result, the State is expected to recover more than $3 billion.